A phase I study of 5-azacytidine (Vidaza) [azacitidine] with interferon alpha 2b in metastatic melanoma patients
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 27 Dec 2007
At a glance
- Drugs Azacitidine (Primary) ; Interferon alpha-2b
- Indications Malignant melanoma
- Focus Adverse reactions
- 27 Dec 2007 The expected completion date for this trial is now 1 May 2007, reported by ClinicalTrials.com.
- 14 Dec 2006 New trial record.